Reading this on a mobile device? Try our optimized mobile version here: http://r.smartbrief.com/resp/ekdBCfbwocfbllcZRpBZ

February 12, 2013
BIO has teamed up with FedEx to offer member companies discounts of up to 35% off select FedEx Express, FedEx Ground and FedEx Home Delivery services through the BIO Business Solutions cost-savings program. Learn more.

The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at bio@smartbrief.com.

  Today's Top Story 
  • N.Y/N.J. slips in life sciences ranking, and Boston still leads
    The greater Boston area held the top spot in Jones Lang LaSalle's ranking of metropolitan life sciences clusters in the U.S. for 2012, while New York/New Jersey fell to No. 2 from the second spot in 2010. In the current rankings, San Diego and the San Francisco Bay Area are second and third, respectively. Ranking fourth through sixth were Raleigh-Durham, Philadelphia and Washington D.C. NJSpotlight.com (New Jersey) (2/11) LinkedInFacebookTwitterEmail this Story
Want big bucks for your company?
You want to sell your business, and you want to ensure that you get the best possible price. By taking 7 simple steps, you can dramatically improve your chances of attracting buyers and getting big bucks for your business. Read the article and learn the 7 steps.

  Health Care & Policy 
  • Oncolytics' Reolysin reduces lung cancer tumors in trial
    Oncolytics Biotech's experimental drug Reolysin, in combination with carboplatin and paclitaxel, was associated with the shrinking of tumors in 95% of patients with metastatic or recurrent squamous cell carcinoma of the lung during a Phase II trial. "Based on these findings we intend to continue to look at Reolysin as a treatment for cancers of the lung and cancers that metastasize to the lung," CEO Brad Thompson said. Reuters (2/8) LinkedInFacebookTwitterEmail this Story
  Company & Financial News 
  • Sanofi plans to buy more shares in Regeneron
    Sanofi plans to increase its stake in longtime drug development partner Regeneron Pharmaceuticals by purchasing shares on the open market. Sanofi holds a 16.7% stake in Regeneron. An agreement gives Sanofi the right to boost its stake in Regeneron to up to 30%. The two companies are jointly developing drugs for rheumatoid arthritis and cholesterol. Reuters (2/11) LinkedInFacebookTwitterEmail this Story
  Global Developments 
The Buzz(CORPORATE ANNOUNCEMENTS)

Interested in learning more about advertising in BIO SmartBrief? Contact Meryl Harold at (202) 407-7828 or mharold@smartbrief.com. 

  Food & Agriculture 
  • Supreme Court to hear case on biotech soybeans
    A case before the U.S. Supreme Court could determine whether Monsanto and other developers of biotech seeds can prevent farmers from making copies of their products. The case concerns an Indiana farmer who bought progeny soybeans from a grain elevator for planting. Monsanto said that a negative ruling "would devastate innovation in biotechnology." Agricultural, medical, and environmental research innovations "depend critically on a strong, stable and nationally uniform system of patent rights and protections," according to BIO. The Washington Post (2/9) LinkedInFacebookTwitterEmail this Story
  Industrial & Environmental 
  • Vilsack: Biofuels can help rural economy
    The Department of Agriculture remains dedicated to strengthening the biofuels industry, including reaching a goal of 14 million gallons of production this year by advanced-biofuels companies, writes Agriculture Secretary Tom Vilsack. "In the months ahead, USDA will continue to provide support for research and infrastructure. At the same time, we'll explore new efforts to provide flexibility for folks all along the supply chain," he writes. The Bladen Journal (Elizabethtown, N.C.) (2/11) LinkedInFacebookTwitterEmail this Story
  News from BIO 
  • BIOtechNOW
    BIOtechNOW is the first in a number of new products from BIO intended to enhance our communications with the biotech community -- not only with our members, but with other stakeholders as well. This e-newsletter, combined with its website, serves as our flagship in that effort. BIOtechNOW will offer original content that emphasizes the business needs of the industry; highlight BIO's advocacy efforts; and provide a portal to all BIO activities and events. Most importantly, it will spotlight for those outside the industry the value of biotechnology. Sign up for the e-newsletter. LinkedInFacebookTwitterEmail this Story
Learn more about BIO ->Conferences  |  Join BIO  |  Media  |  Issues  |  Industry

  SmartQuote 
We spend our time searching for security and hate it when we get it."
--John Steinbeck,
American author


LinkedInFacebookTwitterEmail this Story

 
 
Subscriber Tools
     
Print friendly format | Web version | Search past news | Archive | Privacy policy

Advertise
Account Director:  Meryl Harold (202) 407-7828
 
Read more at SmartBrief.com
A powerful website for SmartBrief readers including:
 
 
 Recent BIO SmartBrief Issues:   Lead Editor:  Tom Parks
     
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
 
 
© 1999-2013 SmartBrief, Inc.® Legal Information